SEARCH

SEARCH BY CITATION

Keywords:

  • thrombosis;
  • embolism;
  • thrombophilia;
  • prothrombin gene

The odds ratio for the FII 20210G/A mutation in 504 patients with venous thromboembolism compared to controls was 2.0 (95% CI 1.0–4.0) and, for factor V Leiden, 5.8 (95% CI 3.3–10.3). 3/504 patients were heterozygous for both mutations. None of the patients had combined natural anticoagulant deficiency and the FII 20210G/A mutation. We conclude that the FII 20210G/A mutation is present in 2.6% of the population and the relative risk of venous thromboembolism in carriers is 2.0.